ErVimmune Unlocks €17M for Groundbreaking Cancer Vaccine Trials
January 23, 2026, 9:39 pm
ErVimmune, a Lyon-based biotech, secured €17 million in Series A funding. This pivotal investment propels its innovative off-the-shelf cancer vaccine, ErVac01, into human clinical trials. The company pioneers therapeutic vaccines targeting "unconventional" tumor antigens derived from human endogenous retroviruses (HERVs). ErVac01 is designed for broad population coverage. It specifically addresses aggressive "cold tumors," including triple-negative breast cancer and ovarian cancer, which resist current immunotherapies. Strategic leadership strengthens with Eric Halioua's appointment as executive chairman. This funding marks a significant advance in developing accessible, ready-to-use cancer treatments, promising new options for patients globally.
ErVimmune achieved a critical financial milestone. The French biotechnology firm closed the first part of its Series A financing. It secured €17 million, or approximately $19.8 million. This capital infusion will fund essential clinical development. Existing investor Seventure Partners participated. New investor SPRIM Global Investments also joined the round. The company anticipates additional non-dilutive funding. Bpifrance and the France 2030 program are expected to provide this support. The Series A round remains open for further investors. Additional capital will accelerate ErVac01 development. It will also broaden the platform’s scope.
ErVimmune focuses on next-generation therapeutic cancer vaccines. These vaccines target unique tumor antigens. They are derived from human endogenous retroviruses (HERVs). HERVs are ancient viral remnants within the human genome. They are typically silent. However, HERVs can reactivate in cancer cells. This reactivation produces distinct protein fragments. The immune system often recognizes these fragments as foreign. This makes HERV-derived antigens prime targets. They are shared across different tumors and patients. This approach differs from personalized cancer therapies.
The company's lead candidate is ErVac01. It is a heterologous vaccine formulation. ErVac01 contains a collection of HERV-derived epitopes. These epitopes are specifically chosen. They aim to cover most of the global population. This broad coverage is based on HLA alleles. Over 95% of Europeans and over 80% of Asians could benefit. The vaccine is designed as an off-the-shelf product. It eliminates the need for patient-specific manufacturing. This provides a ready-to-use solution for widespread deployment.
ErVimmune targets particularly challenging cancers. Its initial focus is on "cold tumors." These tumors often resist current immunotherapies. Checkpoint inhibitors, for example, show limited efficacy. Triple-negative breast cancer (TNBC) is a primary target. TNBC accounts for about 15% of breast cancer cases. It is known for its aggressive nature and poor prognosis. Ovarian cancer is another key indication. It stands as the deadliest gynecological cancer globally. These cancers represent major unmet medical needs. ErVimmune seeks to offer new treatment avenues for these difficult-to-treat diseases.
The funding directly supports a first-in-human clinical trial. This trial is a pivotal step. It will assess ErVac01's safety. It will also evaluate its immunogenicity. A successful outcome will validate the proprietary antigen discovery platform. This step is crucial for future therapeutic candidate generation. The company plans successive waves of candidates. These will target untapped HERV antigens. Expansion across multiple oncology indications is a long-term goal. The clinical phase begins a new chapter for ErVimmune.
Leadership has also strengthened. Biotech veteran Eric Halioua joined ErVimmune. He now serves as executive chairman of the board. Halioua brings a strong track record. He founded and led multiple biotechnology businesses. His experience includes senior roles at PDC*line Pharma and Promethera Biosciences. He also worked at Arthur D. Little's Healthcare & Life Sciences practice. His appointment boosts governance and strategic leadership. He will support clinical execution. He will also drive strategic partnerships and long-term value creation. This aims to build a leading immuno-oncology company.
ErVimmune's financial success reflects a broader trend. Investor interest in European oncology and immuno-oncology remains robust. The 2025-2026 funding landscape shows significant capital flow. Larger, later-stage companies have raised substantial amounts. UK-based Artios Pharma secured €99 million. It expands its precision oncology pipeline. Germany’s Tubulis raised €308 million. It advances its antibody-drug conjugate platform. French companies also recorded major oncology financings. Marseille-based Adcytherix raised €105 million for novel ADC candidates.
ErVimmune’s round aligns with earlier-stage financings. Germany’s T-CURX secured €17.7 million. This supports new cancer treatment development. Switzerland-based Hedera Dx raised €15 million. This Series A funding improves modern cancer care access. Oncology and related biotech rounds during this period total approximately €870 million. ErVimmune's Series A fits within the low-mid range. It signals continued investment in both large-scale platforms and clinic-enabling programs.
ErVimmune originated in 2019. It is a spin-off from the Centre Léon Bérard. The company specializes in therapeutic vaccine development. It focuses on unconventional tumor antigens. Since inception, ErVimmune has received consistent support. Bpifrance, Cancéropôle Lyon Auvergne-Rhône-Alpes, and Agence Nationale de la Recherche (ANR) provided financial aid. Seventure Partners invested in a Seed funding round in late 2020. This was backed by Bpifrance and ANR grants in 2022. An EIC Accelerator grant provided €2.5 million in November 2023. The Paris Saclay Cancer Cluster (PSCC) selected the company for support in 2024. The NETVA program provided further aid in 2025. This layered support highlights ErVimmune's validated potential.
This Series A funding is transformative. It moves ErVimmune into a defining phase. The capital empowers clinical progress. It accelerates a novel approach to cancer treatment. ErVimmune stands poised to reshape immunotherapy. Its off-the-shelf HERV vaccine platform offers new hope. Patients with difficult-to-treat cancers may soon see new options. The future of accessible cancer therapeutics appears brighter.
ErVimmune achieved a critical financial milestone. The French biotechnology firm closed the first part of its Series A financing. It secured €17 million, or approximately $19.8 million. This capital infusion will fund essential clinical development. Existing investor Seventure Partners participated. New investor SPRIM Global Investments also joined the round. The company anticipates additional non-dilutive funding. Bpifrance and the France 2030 program are expected to provide this support. The Series A round remains open for further investors. Additional capital will accelerate ErVac01 development. It will also broaden the platform’s scope.
ErVimmune focuses on next-generation therapeutic cancer vaccines. These vaccines target unique tumor antigens. They are derived from human endogenous retroviruses (HERVs). HERVs are ancient viral remnants within the human genome. They are typically silent. However, HERVs can reactivate in cancer cells. This reactivation produces distinct protein fragments. The immune system often recognizes these fragments as foreign. This makes HERV-derived antigens prime targets. They are shared across different tumors and patients. This approach differs from personalized cancer therapies.
The company's lead candidate is ErVac01. It is a heterologous vaccine formulation. ErVac01 contains a collection of HERV-derived epitopes. These epitopes are specifically chosen. They aim to cover most of the global population. This broad coverage is based on HLA alleles. Over 95% of Europeans and over 80% of Asians could benefit. The vaccine is designed as an off-the-shelf product. It eliminates the need for patient-specific manufacturing. This provides a ready-to-use solution for widespread deployment.
ErVimmune targets particularly challenging cancers. Its initial focus is on "cold tumors." These tumors often resist current immunotherapies. Checkpoint inhibitors, for example, show limited efficacy. Triple-negative breast cancer (TNBC) is a primary target. TNBC accounts for about 15% of breast cancer cases. It is known for its aggressive nature and poor prognosis. Ovarian cancer is another key indication. It stands as the deadliest gynecological cancer globally. These cancers represent major unmet medical needs. ErVimmune seeks to offer new treatment avenues for these difficult-to-treat diseases.
The funding directly supports a first-in-human clinical trial. This trial is a pivotal step. It will assess ErVac01's safety. It will also evaluate its immunogenicity. A successful outcome will validate the proprietary antigen discovery platform. This step is crucial for future therapeutic candidate generation. The company plans successive waves of candidates. These will target untapped HERV antigens. Expansion across multiple oncology indications is a long-term goal. The clinical phase begins a new chapter for ErVimmune.
Leadership has also strengthened. Biotech veteran Eric Halioua joined ErVimmune. He now serves as executive chairman of the board. Halioua brings a strong track record. He founded and led multiple biotechnology businesses. His experience includes senior roles at PDC*line Pharma and Promethera Biosciences. He also worked at Arthur D. Little's Healthcare & Life Sciences practice. His appointment boosts governance and strategic leadership. He will support clinical execution. He will also drive strategic partnerships and long-term value creation. This aims to build a leading immuno-oncology company.
ErVimmune's financial success reflects a broader trend. Investor interest in European oncology and immuno-oncology remains robust. The 2025-2026 funding landscape shows significant capital flow. Larger, later-stage companies have raised substantial amounts. UK-based Artios Pharma secured €99 million. It expands its precision oncology pipeline. Germany’s Tubulis raised €308 million. It advances its antibody-drug conjugate platform. French companies also recorded major oncology financings. Marseille-based Adcytherix raised €105 million for novel ADC candidates.
ErVimmune’s round aligns with earlier-stage financings. Germany’s T-CURX secured €17.7 million. This supports new cancer treatment development. Switzerland-based Hedera Dx raised €15 million. This Series A funding improves modern cancer care access. Oncology and related biotech rounds during this period total approximately €870 million. ErVimmune's Series A fits within the low-mid range. It signals continued investment in both large-scale platforms and clinic-enabling programs.
ErVimmune originated in 2019. It is a spin-off from the Centre Léon Bérard. The company specializes in therapeutic vaccine development. It focuses on unconventional tumor antigens. Since inception, ErVimmune has received consistent support. Bpifrance, Cancéropôle Lyon Auvergne-Rhône-Alpes, and Agence Nationale de la Recherche (ANR) provided financial aid. Seventure Partners invested in a Seed funding round in late 2020. This was backed by Bpifrance and ANR grants in 2022. An EIC Accelerator grant provided €2.5 million in November 2023. The Paris Saclay Cancer Cluster (PSCC) selected the company for support in 2024. The NETVA program provided further aid in 2025. This layered support highlights ErVimmune's validated potential.
This Series A funding is transformative. It moves ErVimmune into a defining phase. The capital empowers clinical progress. It accelerates a novel approach to cancer treatment. ErVimmune stands poised to reshape immunotherapy. Its off-the-shelf HERV vaccine platform offers new hope. Patients with difficult-to-treat cancers may soon see new options. The future of accessible cancer therapeutics appears brighter.